MedTrace Logo

Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost

NCT06449352 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-10-22

No results posted yet for this study

Summary

A randomized, multicenter, investigator-masked prospective study of NTG patients currently on latanoprost 0.005% monotherapy, to study the effect of IOP change with the introduction of netarsudil 0.02% vs brimonidine 0.1%. Subjects will be assessed at a screening visit, and 1 follow-up visit. Clinical evaluations will include visual acuity and IOP .

Conditions

  • Normal Tension Glaucoma

Interventions

DRUG

Netarsudil

netarsudil 0.02%

DRUG

Brimonidine

brimonidine 0.1%

Sponsors & Collaborators

  • Sengi

    collaborator INDUSTRY

  • Westlake Eye Specialists

    lead OTHER

Principal Investigators

  • Zarmeena Vendal, MD · Westlake Eye Specialists

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-06-13
Primary Completion
2025-09-22
Completion
2025-09-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06449352 on ClinicalTrials.gov